 Connection
Anthony Elias to Hematologic Diseases
This is a "connection" page, showing publications Anthony Elias has written about Hematologic Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.203 |
|
|
|
-
Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol. 1994 Oct; 21(5 Suppl 12):83-5.
Score: 0.122
-
Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993 Apr 07; 85(7):559-66.
Score: 0.028
-
Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb; 9(2):320-7.
Score: 0.024
-
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
Score: 0.019
-
Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73.
Score: 0.006
-
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|